DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Safarinejad MR.
Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II study.
Urol Oncol 2008; , in press
We do not assume any responsibility for the contents of the web pages of other providers.